These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 32634775)

  • 41. Immunotherapy in head and neck squamous cell carcinoma: An updated review.
    Parmar K; Mohamed A; Vaish E; Thawani R; Cetnar J; Thein KZ
    Cancer Treat Res Commun; 2022; 33():100649. PubMed ID: 36279709
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Defining an inflamed tumor immunophenotype in recurrent, metastatic squamous cell carcinoma of the head and neck.
    Hanna GJ; Liu H; Jones RE; Bacay AF; Lizotte PH; Ivanova EV; Bittinger MA; Cavanaugh ME; Rode AJ; Schoenfeld JD; Chau NG; Haddad RI; Lorch JH; Wong KK; Uppaluri R; Hammerman PS
    Oral Oncol; 2017 Apr; 67():61-69. PubMed ID: 28351582
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prognostic and predictive factors in recurrent and/or metastatic head and neck squamous cell carcinoma: A review of the literature.
    Bossi P; Alfieri S; Strojan P; Takes RP; López F; Mäkitie A; Saba NF; Rodrigo JP; Bradford C; Suarez C; Zafereo M; Forastiere AA; Vermorken JB; Quer M; Sanabria A; Simo R; de Bree R; Rinaldo A; Ferlito A
    Crit Rev Oncol Hematol; 2019 May; 137():84-91. PubMed ID: 31014517
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trial.
    Caponigro F; Di Gennaro E; Ionna F; Longo F; Aversa C; Pavone E; Maglione MG; Di Marzo M; Muto P; Cavalcanti E; Petrillo A; Sandomenico F; Maiolino P; D'Aniello R; Botti G; De Cecio R; Losito NS; Scala S; Trotta A; Zotti AI; Bruzzese F; Daponte A; Calogero E; Montano M; Pontone M; De Feo G; Perri F; Budillon A
    BMC Cancer; 2016 Nov; 16(1):918. PubMed ID: 27884140
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Novel Systemic Treatment Modalities Including Immunotherapy and Molecular Targeted Therapy for Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma.
    Ghosh S; Shah PA; Johnson FM
    Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887235
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Abscopal Effect Following Immunotherapy and Combined Stereotactic Body Radiation Therapy in Recurrent Metastatic Head and Neck Squamous Cell Carcinoma: A Report of Two Cases and Literature Review.
    Choi JS; Sansoni ER; Lovin BD; Lindquist NR; Phan J; Mayo LL; Ferrarotto R; Su SY
    Ann Otol Rhinol Laryngol; 2020 May; 129(5):517-522. PubMed ID: 31875405
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Expression of immune response biomarkers (PD‑L1, p16, CD3+ and CD8+ TILs) in recurrent head and neck squamous cell carcinoma within previously irradiated areas.
    Pflumio C; Thomas J; Salleron J; Faivre JC; Borel C; Dolivet G; Sastre-Garau X; Geoffrois L
    Oncol Rep; 2021 Mar; 45(3):1273-1283. PubMed ID: 33432367
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Frameshift events predict anti-PD-1/L1 response in head and neck cancer.
    Hanna GJ; Lizotte P; Cavanaugh M; Kuo FC; Shivdasani P; Frieden A; Chau NG; Schoenfeld JD; Lorch JH; Uppaluri R; MacConaill LE; Haddad RI
    JCI Insight; 2018 Feb; 3(4):. PubMed ID: 29467336
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Current studies of immunotherapy in head and neck cancer.
    Dogan V; Rieckmann T; Münscher A; Busch CJ
    Clin Otolaryngol; 2018 Feb; 43(1):13-21. PubMed ID: 28464441
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [The Immune Checkpoints Inhibitors for Head and Neck Cancer].
    Yokota T
    Gan To Kagaku Ryoho; 2019 Jan; 46(1):21-27. PubMed ID: 30765636
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Methotrexate plus or minus cetuximab as first-line treatment in a recurrent or metastatic (R/M) squamous cell carcinoma population of the head and neck (SCCHN), unfit for cisplatin combination treatment, a phase Ib-randomized phase II study Commence.
    Ham JC; van Meerten E; Fiets WE; Beerepoot LV; Jeurissen FJF; Slingerland M; Jonker MA; Husson O; van der Graaf WTA; van Herpen CML
    Head Neck; 2020 May; 42(5):828-838. PubMed ID: 31903657
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Recurrent squamous-cell carcinoma of the head and neck: overview of current therapy and future prospects.
    Ganly I; Kaye SB
    Ann Oncol; 2000 Jan; 11(1):11-6. PubMed ID: 10690381
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Molecularly targeted agents and immunotherapy for the treatment of head and neck squamous cell cancer (HNSCC).
    Azoury SC; Gilmore RC; Shukla V
    Discov Med; 2016 Jun; 21(118):507-16. PubMed ID: 27448787
    [TBL] [Abstract][Full Text] [Related]  

  • 54. HPV16 E5 Mediates Resistance to PD-L1 Blockade and Can Be Targeted with Rimantadine in Head and Neck Cancer.
    Miyauchi S; Sanders PD; Guram K; Kim SS; Paolini F; Venuti A; Cohen EEW; Gutkind JS; Califano JA; Sharabi AB
    Cancer Res; 2020 Feb; 80(4):732-746. PubMed ID: 31848196
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression.
    Ferris RL; Blumenschein G; Fayette J; Guigay J; Colevas AD; Licitra L; Harrington KJ; Kasper S; Vokes EE; Even C; Worden F; Saba NF; Docampo LCI; Haddad R; Rordorf T; Kiyota N; Tahara M; Lynch M; Jayaprakash V; Li L; Gillison ML
    Oral Oncol; 2018 Jun; 81():45-51. PubMed ID: 29884413
    [TBL] [Abstract][Full Text] [Related]  

  • 56. PARTNER: An open-label, randomized, phase 2 study of docetaxel/cisplatin chemotherapy with or without panitumumab as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck.
    Wirth LJ; Dakhil S; Kornek G; Axelrod R; Adkins D; Pant S; O'Brien P; Debruyne PR; Oliner KS; Dong J; Murugappan S
    Oral Oncol; 2016 Oct; 61():31-40. PubMed ID: 27688102
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Current Therapy for Metastatic Head and Neck Cancer: Evidence, Opportunities, and Challenges.
    Wise-Draper TM; Bahig H; Tonneau M; Karivedu V; Burtness B
    Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-14. PubMed ID: 35486888
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Treatment of head and neck squamous cell carcinoma recurrences and distant metastases : Highlights of the 2018 ASCO meeting].
    Bußmann L; Münscher A; Busch CJ
    HNO; 2018 Dec; 66(12):907-912. PubMed ID: 30377743
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Immunotherapy for recurrent/metastatic head and neck cancer.
    Alfieri S; Cavalieri S; Licitra L
    Curr Opin Otolaryngol Head Neck Surg; 2018 Apr; 26(2):152-156. PubMed ID: 29432222
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Optimizing treatments for recurrent or metastatic head and neck squamous cell carcinoma.
    Specenier P; Vermorken JB
    Expert Rev Anticancer Ther; 2018 Sep; 18(9):901-915. PubMed ID: 29999437
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.